Possible Approaches to
 CYP2C9
 -Guided Prescription of Sulfonylureas in Russia

Мосикян, А. А.; Dolgorukova, Antonina; Zalevskaya, Alsu Gafurovna

doi:10.2217/pgs-2016-0121

Cited by 4 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This approach to CYP2C9 genotyping of patients before the treatment by glimepiride has already been adopted in Korea and Russia. 43,44 Our data also provide evidence supporting the use of such an approach.…”

Section: Discussionsupporting

confidence: 69%

The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy

Saberi

Ramazani

Rashidi

et al. 2020

VHRM

View full text Add to dashboard Cite

Aim: Type 2 diabetes (T2D), as a major cause of morbidity and mortality, is predicted to have a prevalence of 629 million by 2045. As diabetic patients show considerable interindividual variation in response to antidiabetic treatment, this study aimed to investigate the gene polymorphism of cytochrome P450 as well as the effectiveness and safety of glibenclamide and gliclazide for different genotypes of CYP2C9. Besides, the chronic side effects of T2D including retinal microvasculature complications or retinopathy and renal dysfunction due to nephropathy in different genotypes were considered. Patients and Methods: The participants including 80 T2D patients treated with glibenclamide or gliclazide were recruited from university hospitals of Ahvaz Jundishpur University of Medical Sciences, Ahvaz, in the southwest of Iran. Blood samples were collected from the patients at 2.5h after the morning dose of glibenclamide and 12h after the last dose of gliclazide. Genotyping from the extracted DNA was, then, performed using PCR-RFLP. The plasma level of glibenclamide and gliclazide was, in turn, measured by the reverse-phase high-pressure liquid chromatography. Results: The results showed that the wild-type allele, i.e., CYP2C9*1, occurred in the highest frequency (0.8), while the frequency rates of the mutant allele, i.e., CYP2C9*2 and CYP2C9*3, were 0.15 and 0.05, respectively. Moreover, no significant association was found between any of the genotypes as well as the clinical and biochemical characteristics of the patients. The findings also showed that the plasma level of sulfonylureas (i.e., glibenclamide and gliclazide) was the highest in the patients with the CYP2C9*3 allele. It was also found that 75.9% of the patients with variant genotypes had experienced hypoglycemia events. Furthermore, in the absence of wild type allele, a significant increase was observed in retinopathy (p=0.039) and nephropathy (p=0.05). Conclusion:The findings can provide guidelines for the optimal management of the treatment protocols with sulfonylurea intended to control the T2D complications.

show abstract

Section: Discussionsupporting

confidence: 69%

The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy

Saberi

Ramazani

Rashidi

et al. 2020

VHRM

View full text Add to dashboard Cite

show abstract

“…Таким образом, несмотря на появление инновационных сахароснижающих препаратов, использование ПСМ остается «базовой» терапевтической опцией, и предсказуемость их фармакологического действия становится чрезвычайно актуальной [28]. Носительство полиморфных маркеров следует учитывать при выборе ПСМ для управления СД 2 [29]. В соответствии с результатами исследования с целью персонификации управления СД 2 необходимо проведение НМГ и генотипирования при выявлении «необъяснимых» гипогликемий или широкой амплитуды гликемии и высокой вариабельности гликемии в пределах гипер-и гипогликемических диапазонов у пациентов, уже принимающих ПСМ.…”

Section: случаиunclassified

The pharmacogenetics of hypoglycemia and the glycemic variability at the patients ith type 2 diabetes mellitus

Chernikova

Камынина

Аметов

et al. 2020

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim.To investigate the link between the hypoglycemia (registrated accurately by the professional Continuous Glucose Monitoring CGM; severe hypoglycemia at home) and the hetero-/homozygote carriage of single nucleotide polymorphisms (SNP) of cytochrome systems geneCYP2C9(rs1799853CYP2C9*2 иrs1057910CYP2C9*3) at the patients with Type 2 Diabetes Mellitus (T2DM) used sulphonylurea (SU). Materials and methods.In Study Case-Control 120 T2DM-SU-patients genotyped by SNPs of geneCYP2C9(using PCR-RT) had been done the professional CGM (System iPro2, Medtronic) recorded Time in Range of Hypoglycemia (TIR-HYPO), level of Minimal CGM-hypoglycemia (MinGl) and standard CGM-parameters of Glycemic Variability. Severe hypoglycemia at home was recorded from visit to visit. The odds ratio (OR) of metabolic disturbances had been assessed for carriage SNPs in comparison with wide alleles. Results.The Study established that carriage of SNPsrs1799853andrs1057910geneCYP2C9at T2DM-SU-patients associated with rising of Glycemic Variability and frequency of CGM-hypoglycemia (MinGl decreasing, increasing of TIR-HYPO and number of Glycemia Excursion 4 mmol/L/h), as well as increasing severe hypoglycemia at home (p0.05). Thus, OR at the carriage ofrs1799853andrs1057910respectively equaled: for CGM-hypoglycemia 7.78 (3.0220.01) and 5.80 (0.23145.87); number of Glycemia Excursion 4 mmol/L/h 5.76 (2.2914.43) and 4.44 (1.4313.76); MinGl3.9 mmol/L 4.39 (1.7910.75) and 6.26 (1.8421.30); CV40% (vs30%) 3.63 (1.0412.62) and 15.22 (0.59393.94);p0.05. Conclusion.At the real clinical practice the assessment of carriage of SNPs of geneCYP2C9before inclusion of SU to glucose-lowering scheme of T2DM-therapy it necessary to carry out for the detecting patients with a higher risk of hypoglycemia and rising of Glycemic Variability.

show abstract

Inhibitory effects characteristics of polysaccharide of Polygonati Rhizome on cytochrome P450 enzymes

Duan,

Wang,

Wang

et al. 2024

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Possible Approaches to CYP2C9 -Guided Prescription of Sulfonylureas in Russia

Abstract: Considering the received data and the existed knowledge on CYP2C9 influence on SUs pharmacokinetics and pharmacodynamics, we propose a possible approach to CYP2C9-guided SUs prescription for Russians.

Cited by 4 publications

References 36 publications

<p>The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy</p>

<p>The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy</p>

The pharmacogenetics of hypoglycemia and the glycemic variability at the patients ith type 2 diabetes mellitus

Inhibitory effects characteristics of polysaccharide of Polygonati Rhizome on cytochrome P450 enzymes

Contact Info

Product

Resources

About